NCT00019396View on ClinicalTrials.gov

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 1998

Study Completion Date

March 31, 2007

Conditions
Stage IV MelanomaStage IV Renal Cell CancerRecurrent Renal Cell CancerRecurrent Melanoma
Interventions
DRUG

flt3 ligand

DRUG

gp100 antigen

DRUG

MART-1 antigen

DRUG

Montanide ISA-51

DRUG

tyrosinase peptide

Trial Locations (1)

20892

Surgery Branch, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH